Why Research On the Pharmacogenetics of Atypical Antipsychotic-Induced Weight Gain in Individuals With Intellectual Disabilities Is Warranted

Weight gain is an often-observed side effect of atypical antipsychotics (AAPs) and is particularly significant in individuals with intellectual disabilities (ID). The majority of individuals treated with AAPs will gain at least 10% of their initial body weight over the course of therapy ( Umbricht &...

Full description

Saved in:
Bibliographic Details
Published in:Journal of mental health research in intellectual disabilities 2011-06, Vol.4 (2), p.65-78
Main Authors: Sleister, Heidi M., Valdovinos, Maria Gabriela
Format: Article
Language:English
Subjects:
atypical antipsychotics
Body Weight
Drug Therapy
Genetics
intellectual disabilities
Learning disabilities
Mental Retardation
Patients
psychopharmacogenetics
Psychopharmacology
Psychosis
Psychotropic drugs
Weight control
weight gain
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Weight gain is an often-observed side effect of atypical antipsychotics (AAPs) and is particularly significant in individuals with intellectual disabilities (ID). The majority of individuals treated with AAPs will gain at least 10% of their initial body weight over the course of therapy ( Umbricht & Kane, 1996 ). One's genetic constitution is an important factor that influences the variability of weight gain observed among patients taking AAPs. This article reviews the existing literature on psychopharmacogenetics of AAP-induced weight gain and the importance of this research for individuals with ID.
ISSN:1931-5864
1931-5872
DOI:10.1080/19315864.2011.555600